Combination of Metformin, Sodium Oxamate and Doxorubicin Induces Apoptosis and Autophagy in Colorectal Cancer Cells Downregulation HIF-1α
Overview
Authors
Affiliations
Colorectal cancer (CRC) is the third leading cause of cancer-related death worldwide in both sexes. Current therapies include surgery, chemotherapy, and targeted therapy; however, prolonged exposure to chemical agents induces toxicity in patients and drug resistance. So, we implemented a therapeutic strategy based on the combination of doxorubicin, metformin, and sodium oxamate called triple therapy (Tt). We found that Tt significantly reduced proliferation by inhibiting the mTOR/AKT pathway and promoted apoptosis and autophagy in CRC derived cells compared with doxorubicin. Several autophagy genes were assessed by western blot; ULK1, ATG4, and LC3 II were overexpressed by Tt. Interestingly, ULK1 was the only one autophagy-related protein gradually overexpressed during Tt administration. Thus, we assumed that there was a post-transcriptional mechanism mediating by microRNAs that regulate UKL1 expression during autophagy activation. Through bioinformatics approaches, we ascertained that ULK1 could be targeted by mir-26a, which is overexpressed in advanced stages of CRC. experiments revealed that overexpression of mir-26a decreased significantly ULK1, mRNA, and protein expression. Contrariwise, the Tt recovered ULK1 expression by mir-26a decrease. Due to triple therapy repressed mir-26a expression, we hypothesized this drug combination could be involved in mir-26a transcription regulation. Consequently, we analyzed the mir-26a promoter sequence and found two HIF-1α transcription factor recognition sites. We developed two different HIF-1α stabilization models. Both showed mir-26a overexpression and ULK1 reduction in hypoxic conditions. Immunoprecipitation experiments were performed and HIF-1α enrichment was observed in mir-26a promoter. Surprisingly, Tt diminished HIF-1α detection and restored ULK1 mRNA expression. These results reveal an important regulation mechanism controlled by the signaling that activates HIF-1α and that in turn regulates mir-26a transcription.
Flores-Garcia L, Garcia-Castillo V, Perez-Toledo E, Trujano-Camacho S, Millan-Catalan O, Perez-Yepez E Cells. 2025; 14(5).
PMID: 40072116 PMC: 11898799. DOI: 10.3390/cells14050388.
Kim J, Shin H, Kim W, Park E, Lee D, Lee Y Sci Rep. 2025; 15(1):6658.
PMID: 39994354 PMC: 11850875. DOI: 10.1038/s41598-025-91022-y.
Non-coding RNAs as potential targets in metformin therapy for cancer.
Zhang Y, Wu Y, Liu Z, Yang K, Lin H, Xiong K Cancer Cell Int. 2024; 24(1):333.
PMID: 39354464 PMC: 11445969. DOI: 10.1186/s12935-024-03516-w.
Ugur E, Tidim G, Gundogdu D, Alemdar C, Oral G, Husnugil H ACS Omega. 2024; 9(38):39626-39642.
PMID: 39346850 PMC: 11425960. DOI: 10.1021/acsomega.4c03977.
Obesity-Associated Colorectal Cancer.
Gonzalez-Gutierrez L, Motino O, Barriuso D, de la Puente-Aldea J, Alvarez-Frutos L, Kroemer G Int J Mol Sci. 2024; 25(16).
PMID: 39201522 PMC: 11354800. DOI: 10.3390/ijms25168836.